Whilst EU pharma industry flags, Eucomed enjoys a period of relative tranquillity
This article was originally published in RAJ Devices
Executive Summary
Mr Wilkinson maintains that the regulatory environment in Europe makes it generally a good place in which to operate. “It’s not all rosy though, because clearly there are challenges for emerging companies, particularly SMEs [small-to-medium-sized businesses] in terms of raising finance – although I suspect that is a global issue now,” he offers.
You may also be interested in...
MHRA’s Beneficial EU Relationship And Profitable Synergies With NICE: An Interview With Michael Rawlins
In December, Michael Rawlins was appointed head of the U.K.’s Medicines and Healthcare products Regulatory Agency. He recognizes the MHRA’s mutually beneficial relationship with European counterparts and is looking to safeguard synergies with other national regulatory bodies and NICE.
EMA Acts To Freeze GVK Drugs, Guard Against Shortages
The EMA has recommended suspension of some 700 drug formations linked with Indian clinical trials company GVK Biosciences, but assures national agencies that this won’t result in shortages or safety issues.
EMA Acts To Freeze Drugs Linked to GVK Bio, Guards Against Shortages
EMA has recommended suspension of some 700 drug formations linked with Indian clinical trials company GVK Biosciences, but assures national agencies that this won’t result in shortages or safety issues.